PureTech Health PLC First Capital Markets Meeting
May 10 2016 - 2:00AM
RNS Non-Regulatory
TIDMPRTC
PureTech Health PLC
10 May 2016
10 May 2016
PureTech Health plc
First Capital Markets Meeting
PureTech Health plc ("PureTech", LSE: PRTC), a
cross-disciplinary healthcare company tackling fundamental
healthcare needs in disruptive ways, is today holding its first
Capital Markets Meeting as a London Listed Company. The Company
will provide insight into its strategy, progress of the Company's
pipeline, and insights into new areas of unmet medical need being
explored. No new material information will be disclosed.
The meeting will take place in London from 13.00-17.00 BST and
will feature PureTech presenters including members of the Company's
Board of Directors.
Presenters at the event include:
-- Daphne Zohar, Co-Founder & CEO of PureTech
-- Joi Ito, Chairman of the Board of Directors of PureTech; Director of the MIT Media Lab
-- Raju Kucherlapati, PhD, Independent Non-Executive Director,
Scientific Advisory Board Member of PureTech; Co-Founder of
Millennium Pharmaceuticals and Abgenix
-- John LaMattina, PhD, Independent Non-Executive Director of
PureTech; former President of Pfizer Global Research and
Development
-- Marjorie Scardino, Senior Independent Director of PureTech;
former CEO of The Economist and of Pearson plc, Chairman of the
MacArthur Foundation Board
-- Ben Shapiro, MD, Co-Founder & Non-Executive Director of
PureTech; former Executive Vice President of Research for Merck
-- Christopher Viehbacher, Independent Non-Executive Director of PureTech; former CEO of Sanofi
-- Joseph Bolen, PhD, Entrepreneur-In-Residence, PureTech;
former President and Chief Scientific Officer at Moderna
Therapeutics and former Chief Scientific Officer and Global Head of
Oncology Research at Millennium
-- Marko Ahtisaari, CEO and Co-Founder of the Sync Project
-- Bernat Olle, PhD, CEO of Vedanta Biosciences
-- Jan Skvarka, President, CEO of Tal Medical
-- Eddie Martucci, PhD, CEO of Akili Interactive Labs
-- Additional members of the PureTech leadership team
If you would like to attend the event, please contact
PureTech.Event@fticonsulting.com.
About PureTech Health
PureTech Health (PureTech Health plc, PRTC.L) is a
cross-disciplinary healthcare company developing innovative
products that could improve the lives of billions of patients.
PureTech is focused on areas of growing scientific and technical
insights that it believes are at an important inflection point,
including the central nervous, gastro-intestinal and immune
systems, and the interactions and signalling between them. PureTech
has a pipeline of more than 30 programmes and has approximately 20
clinical studies across its pipeline, targeting multi-billion
dollar market opportunities. PureTech's advanced programmes include
five with human proof-of-concept and multiple with pivotal or
registration study readouts in the next two years. PureTech's
leading team and board, along with an advisory network of more than
60 expert founder-scientists and advisors across multiple
disciplines, gives PureTech access to potentially ground-breaking
science and technological innovation. With healthcare undergoing
major transformation, PureTech believes it is well positioned to
develop and launch medicines for the 21st century. For more
information, visit http://www.puretechhealth.com and connect with
us on Twitter.
Enquiries
PureTech
Julie DiCarlo, Senior Vice President,
Communications and Investor Relations +1 617 226.4819
FTI Consulting (Communications adviser
to PureTech)
Ben Atwell +44 (0) 20
Matthew Cole 3727 1000
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGGUQGAUPQUAU
(END) Dow Jones Newswires
May 10, 2016 02:00 ET (06:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024